A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
ER+ HER2- Advanced Breast Cancer · High-grade Serous Ovarian Cancer (HGSOC)
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 55 (final count)
- Started
- Dec 5, 2023
- Main results expected
- Jun 30, 2027
- Fully finished
- Jun 30, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of dose limiting toxicities (DLTs) as defined in the protocol.
Measured over: From start of treatment until the end of DLT period, assessed up to 28 days.
Incidence of AEs/SAEs
Measured over: From start of treatment until the end of safety follow-up, approximately 18 months.
Clinically significant changes from baseline in clinical laboratory parameters, vital signs and ECGs.
Measured over: From start of treatment until the end of safety follow-up, approximately 18 months.
Discontinuation of AZD8421 due to toxicity
Measured over: From start of treatment until the end of safety follow-up, approximately 18 months.
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06188520 · record last updated 2026-10-28 · checked 2026-11-09 15:47 UTC